Receptor occupancy measurement by flow cytometry is a rapid, quantifiable and an important addition to PK and PD data in the biopharmaceutical development process.
In this article, details of the tailored solutions KCAS (KS, USA) offers for flow cytometry are discussed including 13 prequalified biomarker immune monitoring panels for support of clinical trials.
Tumor microenvironment monitoring: isolation and flow cytometric immunophenotyping of exosomes from human plasma
In this poster, KCAS (KS, USA) discuss isolation and flow cytometric immunophenotyping of exosomes from human plasma.
Find out more about the current research focuses at KCAS Bioanalytical & Biomarker Services and how the industry has evolved over the last 5–10 years in this interview with John Bucksath (KCAS).
Types of anti-drug antibody regulated methods validated in the last 12 months at KCAS Bioanalytical & Biomarker Services
Find out more about the types of Anti-Drug Antibody (ADA) regulated methods validated in the last 12 months at KCAS Bioanalytical & Biomarker Services.
Find out more an electrochemiluminescent bridging immunogenicity assay used to measure anti-drug antibodies in human serum using an acid dissociation step in this poster from KCAS Bioanalytical & Biomarker Services (KS, USA).
Webinar available to view on demand. In this free panel discussion, our experts will provide insights into their own research with immunogenicity including the challenges they have had to overcome, key trends they have seen and their future outlook of the development of this field.
Immunogenicity is the patient’s ability to generate antibodies, specific to the ‘dosed protein therapeutic’. In this blog post, Franklin Spriggs (KCAS; KS, USA) explains the importance of antibody-drug antibody assays and how data can be used towards safety profiles.
In this Spotlight interview, Franklin Spriggs (KCAS; KS, USA) explains his interest in biomarkers and introduces the technologies and techniques utilized and offered by KCAS.
Available to view on demand. We present a rare opportunity to see experts from across the pharmaceutical and CRO industries sharing perspectives on new technology integration in the field of bioanalysis.